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Reactivation of functionally-impaired anticancer T cells by PD-1/PD-L1-blocking antibodies 
shows prominent therapeutic benefit in advanced melanoma and NCSLC patients. However, 
current PD-L1-blocking antibodies lack intrinsic tumor-selectively. Therefore, efficacy may 
be reduced due to ‘on-target/off-tumor’ binding to PD-L1-expressing normal cells. This may 
lead to indiscriminate activation of antigen-experienced T cells, including those implicated in 
autoimmune-related adverse events. To direct PD-L1-blockade to CSPG4-expressing cancers 
and to reactivate anticancer T cells more selectively we constructed bispecific antibody 
(bsAb) PD-L1xCSPG4. CSPG4 is an established target antigen that is selectively 
overexpressed on malignant melanoma and various other difficult-to-treat cancers. PD-
L1xCSPG4 showed enhanced capacity for CSPG4-directed blockade of PD-L1 on cancer 
cells. Importantly, treatment of mixed-cultures contai ing primary patient-derived CSPG4-
expressing melanoma cells and autologous tumor-infiltrating lymphocytes with PD-
L1xCSPG4 significantly enhanced activation status, IFN-γ production, and cytolytic activity 
of anticancer T cells. In conclusion, tumor-directed blockade of PD-L1 by PD-L1xCSPG4 
may improve efficacy and safety of PD-1/PD-L1 checkpoint blockade for treatment of 

















Malignant melanoma is the most lethal type of skin ca cer and its incidence is rising at an 
alarming rate of approximately 1.5% annually over the last decade (National Cancer Institute, 
2018). When diagnosed at an early stage, localized m lanoma can be treated by radical 
removal of the lesion, resulting in excellent survival rates. However, once progressed to the 
metastatic stage, the options for curative treatmens are limited. Recently, immune checkpoint 
PD-1-blocking antibodies nivolumab and pembrolizumab h ve shown remarkable benefit for 
a subgroup of patients suffering from metastatic cancer, including malignant melanoma 
(Sullivan and Flaherty, 2015, Wolchok et al, 2017). However, systemic administration of both 
PD-1 and PD-L1-blocking antibodies carries the potential risk of inducing serious immune-
related adverse events (irAEs) (Pen et al, 2014). Moreover, the efficacy of current PD-1/PD-
L1-blocking antibodies may be reduced due to on-target/off-tumor binding to a surplus of 
normal cells also expressing PD-L1, which may preclude sufficient antibody accumulation at 
the tumor site..  
Therefore, we developed a bispecific antibody which aims to locally reactivate anticancer T 
cells by directing PD-L1-blockade to CSPG4 expressed on the surface of tumor cells. 
Chondroitin sulfate proteoglycan 4 (CSPG4), also knw  as MCSP, NG2 (Nishiyama et al, 
1991) and HMW-MAA (Wilson, Ruberto and Ferrone, 1983) is a type 1 transmembrane 
protein that consists of two components - an N-linked 280 kDa glycoprotein component and a 
450 kDa chondroitin sulfate proteoglycan component. CSPG4 is selectively overexpressed on 
several difficult-to-treat cancer types, including melanoma, mesothelioma (Rivera et al, 
2012), triple-negative breast cancer (TNBC) (Wang et al, 2010), and glioblastoma (Svendsen 
et al, 2011). Importantly, more than 90% of melanoma lesions overexpress CSPG4 (Campoli 
et al, 2004). Consequently, CSPG4 is considered a promising target antigen for antibody-
















cancer-selective expression of CSPG4 prompted us to construct a bsAb that allows for 
CSPG4-directed blockade of the PD-1/PD-L1 immune chckpoint. This targeted approach 




















PD-L1xCSPG4 binds to both PD-L1 and CSPG4  
PD-L1xCSPG4 showed potent and dose-dependent binding to CHO.PD-L1 hamster cells 
ectopically expressing human PD-L1 and essentially no binding to PD-L1neg wt CHO cells 
(Fig. 1a). Importantly, PD-L1xCSPG4 showed enhanced binding to CSPG4pos/PD-L1pos 
MDA-MB-231.CSPG4+++ breast cancer cells compared to CSPG4low/PD-L1pos wt MDA-
MB-231 cells (Fig. 1b). Furthermore, binding of PD-L1xCSPG4 to CSPG4pos/PD-L1pos 
A375m melanoma cells was strongly reduced in the presence of excess amounts of the 
parental anti-CSPG4 antibody mAb 9.2.27, whereas presence of excess amounts of a 
competing PD-L1-blocking mAb only marginally inhibited cancer cell binding (Fig. 1c). 
Thus, PD-L1xCSPG4 binds to both PD-L1 and CSPG4 and its binding to CSPG4pos/PD-L1pos 
melanoma cells is dominated by binding to overexpressed CSPG4. Of note, binding data of 
PD-L1xCSPG4 to a series of PD-L1pos/CSPG4pos cell lines closely correlated with expression 
levels of CSPG4 on the respective cell lines (Fig. 1d and e), whereas binding of PD-
L1xMock, a PD-L1-blocking bsAb equipped with an irrelevant second binding specificity, 
was correlated only with PD-L1 expression levels (suppl. Fig. 2a-c). 
The enhanced binding affinity (avidity) ofPD-L1xCSPG4 for CSPG4pos/PD-L1pos cancer cells 
was evaluated in a competitive cell binding assay with fluorescently-labeled anti-PD-L1 mAb. 
Using this assay, the IC50 value of PD-L1xCSPG4 for displacing an APC-labeled PD-L1 
mAb bound to A375m melanoma cells was calculated to be 4.6 ng/ml, ~100 times lower than 
that of control bsAb PD-L1xMock. Importantly, in the presence of a molar excess of CSPG4-
competing mAb 9.2.27 the IC50 value of PD-L1xCSPG4 increased to that of PD-L1xMock 
(Fig. 1f).  
Taken together, these data demonstrated that PD-L1xCSPG4 has markedly enhanced avidity 

















CSPG4-directed PD-1/PD-L1 blockade by PD-L1xCSPG4 
CSPG4-independent PD-L1-blocking capacity of PD-L1xCSPG4 was evaluated using a 
commercially available bioassay in which antibody-induced release of the PD-1/PD-L1-
mediated break on luciferase production in Jurkat.PD1-NFAT-luc cells by CHO.PD-L1/CD3 
cells is evaluated by an increase in bioluminescence. In this assay, PD-L1xCSPG4 and PD-
L1xMock dose-dependently inhibited PD-1/PD-L1 interaction with similar IC50 values of 
2.07 and 2.99 µg/ml, respectively. Notably, the PD-L1-blocking activity of antibody 
MEDI4736 proved to be significantly higher (IC50 = 0.09 µg/ml) (Fig. 2a). 
Next, the capacities for CSPG4-directed PD-1/PD-L1 blockade of PD-L1xCSPG4, PD-
L1xMock and MEDI4736 were compared using an adapted version of the aforementioned 
PD-1/PD-L1 bioassay by exchanging CHO.PD-L1/CD3 cells with A375m.EpCAM 
melanoma cells stably transfected with EpCAM and pretreated with BIS-1; an EpCAM-
directed CD3-agonistic bsAb, essentially as previously described by us (Kroesen et al, 1997, 
Koopmans et al, 2018). PD-L1xCSPG4 showed an enhanced capacity to unleash  the PD-
1/PD-L1-mediated break on luminescence by Jurkat.PD1-NFAT-luc cells compared with PD-
L1xMock (Fig. 2b). However, when binding to CSPG4 on A375m.EpCAM melanoma cells 
was precluded by pretreatment with parental anti-CSPG4 antibody mAb 9.2.27, the ability of 
PD-L1xCSPG4 to block PD-1/PD-L1 interaction was reduced to that of PD-L1xMock (Fig. 
2c). 
Together, this indicates that the PD-L1-blocking capacity of PD-L1xCSPG4 towards 
CSPG4neg cells is notably lower than that of MEDI4736 and comparable to that of PD-
L1xMock. However, upon CSPG4-binding the PD-L1-blocking activity of PD-L1xCSPG4 

















PD-L1xCSPG4 promotes activation status of antigen-experienced T cells 
In a mixed lymphocyte reaction (MLR) of CFSE-labeled PBMCs and allogeneic DCs, 
treatment with PD-L1xCSPG4,PD-L1xMock or MEDI4736 enhanced the capacity of T cells 
to proliferate and secrete IFN-γ (Fig. 3a and b). Subsequently, we evaluated PD-L1xCSPG4 
for its capacity to enhance the activity of antigen-experienced T cells. For this, PBMCs 
derived from CMV-seropositive and CMV-seronegative healthy subjects were incubated with 
recombinant CMV protein pp65 and then cultured in the presence of PD-L1xCSPG4 or 
control antibodies. Of note, incubation of PBMCs with pp65 protein results in phagocytic 
processing and subsequent cross-presentation of pp65-derived peptides in the context of the 
respective autologous HLA-class 1 haplotype. Treatmnt of pp65-loaded PBMCs with PD-
L1xCSPG4 or MEDI4736 increased the secretion of IFN-γ and Granzyme B by autologous T 
cells derived from CMV-seropositive subjects, but no from CMV-seronegative subjects (Fig. 
3c and d). Taken together, like MEDI4736, PD-L1xCSPG4 and PD-L1xMock have capacity 
to enhance proliferation, Granzyme B and IFN-γ secretion by antigen-experienced T cells. 
 
PD-L1xCSPG4 enhances anticancer activity of T cells in a CSPG4-directed manner 
Next, we assessed the ability of PD-L1xCSPG4 to  prmote anticancer activity of T cells in a 
CSPG4-directed manner. First, a treatment regime was applied in which mixed cultures of T 
(effector) cells and CSPG4pos A375m melanoma (target) cells were treated in the continuous 
presence of PD-L1xCSPG4 or control antibodies for 48 h, after which induction of IFN-γ 
production by T cells was detected by an ELISpot assay. Under this regime, the amount of 
IFN-γ spots induced by PD-L1xCSPG4 was higher than induce  by the various control 
antibodies (Fig. 4a and b).  
Subsequently, we evaluated a treatment regime in which T cells were mixed with either 
















L1xCSPG4, PD-L1xMock or MEDI4736 for only 1 h, after which unbound antibody was 
removed and treatment was allowed to continue for 48 h. Under this regime, PD-L1xCSPG4 
showed enhanced capacity to induce T cell produced IFN-γ spots when cocultured with 
CSPG4pos A375m and SK-MEL-28 cancer target cells, but not with CSPG4neg FaDu cancer 
cells (Fig. 4c). Of note, the inter-donor variation in (normal) immune responses, e.g. in 
individual IFN-γ response levels, is reflected in the variation observed in the amount of IFN-γ 
ELIspots as detected for the individual donors in Fig. 4a. 
 
PD-L1xCSPG4 enhances anticancer activity of TILs towards autologous patient-derived 
melanoma cells 
Primary melanoma cells and autologous tumor-infiltrating lymphocytes derived from 5 
patients were short-term cultured in vitro. The melanoma cells were assessed for cell surface 
expression of CSPG4 en PD-L1 by flow cytometry, which revealed that 5 out of 5 tumor 
specimens expressed both CSPG4 and PD-L1 (Fig. 5a and b). Importantly, in coculture 
experiments PD-L1xCSPG4 enhanced the anticancer activity of TILs towards autologous 
patient-derived melanoma cells, which was evident from an up to 25% increase in apoptotic 
cancer cell death compared to medium control (Fig. 5c). Moreover, MEDI4736 also enhanced 
the anticancer activity of TILs towards autologous patient-derived melanoma cells up to 10%, 
whereas MockxCSPG4 did not. The increase in oncolyti  activity of TILs by PD-L1xCSPG4 
and MEDI4736 treatment was accompanied by an increase in their capacity to express CD25 
(Fig. 5d) and secrete IFN-γ (Fig. 5e). Taken together, these results indicate that PD-
L1xCSPG4 enhances activation status and anticancer activity of TILs towards autologous 
patient-derived melanoma cells. Of note, CSPG4 expression on patient-derived melanom  
















without further signal amplification to minimize handling steps. Consequently, the CSPG4 




Current FDA-approved PD1/PD-L1-blocking antibodies show prominent therapeutic activity, 
particularly in advanced NSCLC and melanoma patients. However, these antibodies lack 
tumor-selective binding activity and may indiscriminately reactivate antigen-experienced T 
cells, including potentially harmful autoreactive T cells. Recently, we reported that NSCLC-
directed PD-1/PD-L1 blockade can be significantly enhanced through the use of bsAb PD-
L1xEGFR that directs PD-L1-blockade to EGFR-overexpssing cancer cells in vitro and 
shows enhanced tumor-selective localization in nude mice xenografted with EGFR-positive 
tumors (Koopmans et al, 2018). 
For the current study, we extended this approach to melanoma cells by constructing bsAb PD-
L1xCSPG4. CSPG4 appears a promising target antigen for this approach because of its 
overexpression on more than 90% of melanoma lesions and its absence on adult healthy 
tissues. Moreover, CSPG4 is implicated in various malignant features of melanoma. In 
particular, CSPG4 signaling stimulates growth, motility, and tissue invasion by melanoma 
cells, e.g. by enhancing integrin function (Eisenman et al, 1999), activation of Focal 
Adhesion Kinase (FAK) (Yang et al, 2004), mitogenic ERK signaling (Yang et al, 2009) and 
matrix metalloproteinase 2 (Iida et al, 2007). Additionally, CSPG4 is also expressed on 
various other difficult-to-treat malignancies, including mesothelioma (Rivera et al, 2012), 

















Our binding analyses demonstrated that PD-L1xCSPG4 simultaneously binds to PD-L1 and 
CSPG4 and that this concurrent binding enhances avidity of binding to PD-L1pos/CSPG4pos 
cancer cells. Of note, bsAb PD-L1xCSPG4 not only binds with enhanced affinity to cancer 
cells that express both CSPG4 and PD-L1, but can also can bridge two different cell types that 
express either of these target antigens and thereby modulate intercellular contacts (see suppl. 
Fig. 3 a and b). The latter may further add to the tumor-directed activity of PD-L1xCSPG4 as 
it may locally block the immune suppressive activity of tumor-infiltrating leukocytes such as 
myeloid-derived suppressor cells (MDSCs) that are known to exert their suppressive action by 
expressing elevated cell surface levels of PD-L1 in the tumor microenvironment.  
Using a modified bioassay, we demonstrated that the enhanced avidity of PD-L1xCSPG4 for 
PD-L1pos/CSPG4pos cancer cells resulted in strong PD-L1-blocking activity, similar to that of 
high-affinity PD-L1-blocking antibody MEDI4736. Importantly, compared to MEDI4736 the 
PD-L1-blocking activity of PD-L1xCSPG4 towards PD-L1pos/CSPG4neg cells was clearly 
lower. Thus, the PD-L1-blocking capacity of PD-L1xCSPG4 is increased to that of 
MEDI4736, but only upon concurrent binding to cancer ll surface-expressed CSPG4. This 
unique feature of PD-L1xCSPG4 may be attributable to its particular bispecific taFv-Fc 
format in which the carboxyl terminus of each PD-L1-blocking scFv antibody domain is fused 
to the amino terminus of each CSPG4-directed scFv antibody domain, interspersed by only a 
short linker sequence (suppl. Fig. 1a). Previously, it was demonstrated that linker composition 
and/or length used in this class of bsAbs can reduc accessibility to either or both target 
antigens (Piccione et al, 2015, Wu et al, 2009).  
Our results indicated that, like MEDI4736, PD-L1xCSPG4 promotes the activation statu of 
antigen-experienced T cells. In particular, treatment of pp65 peptide-presenting PBMCs with 
















subjects, and not from CMV-seronegative subjects, to proliferate and secrete IFN-γ and 
Granzyme B. 
Importantly, our data indicated that PD-L1xCSPG4 promotes the activation status of T cells 
towards cancer cells in a CSPG4-directed manner. This unique feature of PD-L1xCSPG4 was 
particularly prominent in a regime in which mixed cultures of T cells with either CSPG4pos or 
CSPG4neg cancer cells were briefly treated for 1 h, after which unbound antibody was washed 
away. Under this regime, PD-L1xCSPG4 enhanced the capacity of T cells to produce IFN-γ, 
but only when cocultured with CSPG4pos melanoma cells and not with CSPG4neg cells. 
Moreover, PD-L1xCSPG4 enhanced the activation statu nd anticancer activity of TILs 
towards corresponding autologous patient-derived PD-L1pos/CSPG4pos melanoma cells.  
Apart from the above characteristics, PD-L1xCSPG4 may also have other anticancer activities 
not addressed here. For instance, it is reported that the anti-CSPG4 mAb 9.2.27 used to 
construct PD-L1xCSPG4 has capacity to inhibit anchorage-independent growth of human 
melanoma cells (Harper and Reisfeld, 1983). It is tentative to speculate that this activity is 
retained in bsAb PD-L1xCSGP4 and that concurrent blockade of PD-L1 may result in further 
sensitization of melanoma cells to therapy. Additionally, PD-L1xCSPG4 is equipped with a 
human IgG1 domain which may be beneficial to selectiv ly eliminate PD-L1pos/CSPG4pos 
cancer cells by NK cell-mediated ADCC. Indeed, it was recently demonstrated that PD-L1-
blocking avelumab, engineered with a human IgG1 domain, has NK cell-mediated ADCC 
activity that enhanced its therapeutic functionality with a toxicity profile similar to ADCC-
null mutated PD-L1-blocking antibodies (Boyerinas et al, 2015, Fujii et al, 2016).  
Taken together, bispecific antibody PD-L1xCSPG4 may be useful to enhance selectivity, 
efficacy and safety of PD-1/PD-L1 checkpoint blockade for treatment of melanoma and other 

















MATERIALS AND METHODS  
Antibodies and Reagents 
Goat anti-human Ig-PE (Southern Biotech, Birmingham, AL), anti-PD-L1-APC (clone 
29E.2A3, BioLegend, San Diego, CA), anti-CSPG4-FITC (clone LHM2, Santa Cruz 
Biotechnologies, CA), anti-CSPG4-PE (clone 9.2.27, BD Biosciences, Franklin Lakes, NJ), 
anti-CD3-PerCP-Cyanine5.5 (clone OKT-3, all eBioscien e, Waltham, MA), and anti-CD3-
FITC (clone Ucht1), anti-CD8-FITC, APC (clone HIT8a), nti-CD56-PE (clone B-A19), anti-
CD14-FITC, PE (clone MEM-15), anti-CD25-FITC, APC (clone MEM-181), mouse IgG1-
FITC, PE, Mouse IgG2b-APC, Annexin-V-FITC (all Immunotools, Friesoythe, Germany). 
CSPG4-blocking mAb was from BioLegend, clone 9.2.27. PD-L1-blocking mAb was from 
BPS Bioscience (San Diego, CA). Secretion of cytokines by T cells was measured using 
appropriate ELISA kits (IFN-γ from eBioscience and granzyme B from Mabtech, Nacka 
Strand, Sweden). 
 
Cell lines and transfectants 
Cell lines A2058, A375m, G43, SK-MEL-28, HT1080, MDA-MB-231, FaDu, H292, LNCaP, 
22Rv1 and CHO-K1 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). Cell lines were authenticated by short tandem repeat (STR) analysis and 
regularly checked for mycoplasma infection. Cells were cultured in RPMI-1640 or DMEM 
(Lonza, Bazel, Swiss), supplemented with 10% fetal calf serum (FCS, Thermo Scientific 
Waltham, MA), CHO-K1 cells were cultured in GMEM (First Link, Wolverhampton, UK), 
supplemented with 5% dialyzed FBS (Sigma Aldrich) at 37°C in a humidified 5% CO2 
atmosphere. CHO.PD-L1 cells stably expressing human PD-L1 were generated by lipofection 
(Fugene-HD, Promega, Madison, WI) with plasmid pCMV6-PD-L1 (Origene, Rockville 
















EpCAM-YFP (a kind gift from Dr. Olivier Gyres, Munich, Germany). Cell line MDA-MB-
231.CSPG4+++ (Ilieva et al, 2018) was a kind gift from Dr. Sophia N. Karagiannis (King’s 
college Londen, United Kingdom). CSPG4 and PD-L1 expr ssion was analyzed for all cell 
lines by flow cytometry using anti-CSPG4-PE and anti-PD-L1-APC antibodies and 
appropriate isotype controls. The relative expression levels of CSPG4 and PD-L1 are listed in 
suppl. Table 1. 
 
Construction of bsAb PD-L1xCSPG4 
DNA fragments encoding scFvPD-L1 and scFv 9.2.27 were generated by commercial gene 
synthesis service (Genscript, Piscataway, NJ) based on published VH and VL sequence data 
of PD-L1-blocking antibody 3G10 and CSPG4-directed mAb 9.2.27, respectively. For 
construction and production of PD-L1xCSPG4 we used eukaryotic expression plasmid 
pEE14-bsAb (He et al, 2016), which contains 3 consecutive multiple cloning sites (MCS). 
MCS#1 and MCS#2 are interspersed by a 22 amino acid flexible linker derived from a CH1 
IgG domain (Helfrich et al, 2000). MCS#1, MCS#2 and MCS#3 were used for directional and 
in-frame insertion of DNA fragments encoding scFvPD-L1, scFv9.2.27, and human Fc 
(IgG1), respectively, yielding plasmid pEE14-PD-L1xCSPG4 (suppl. Fig. 1a and b). 
 
SDS-PAGE analysis of PD-L1xCSPG4 
Protein A-purified PD-L1xCSPG4 or MEDI4736 (2,5µg) were separated by SDS-PAGE 
(10% acrylamide) under reducing or nonreducing conditions, followed by staining of the gel 



















Eukaryotic production of recombinant bsAbs 
PD-L1xCSPG4 was produced using CHO-K1 cells transfected with eukaryotic expression 
plasmids pEE14-PD-L1xCSPG4, using the Fugene-HD reagent (Promega) and stable 
transfectants were generated by the glutamine synthetase selection method. Stable 
transfectants were cultured at 37°C in serum-free CHO-S SFM II suspension medium (Gibco, 
Life Technologies, Waltham, MA) for up to 7 days after which supernatant was harvested 
(3000 x g, 30 min). PD-L1xCSPG4 was purified using a HiTrap protein A HP column 
connected to an ÄKTA Start chromatography system (GE Healthcare Life Sciences, Little 
Chalfont, UK). 
 
Binding activity of PD-L1xCSPG4 for PD-L1 and CSPG4 
PD-L1-selective binding activity of PD-L1xCSPG4 was confirmed by comparing binding to 
CHO.PD-L1 cells versus parental CHO cells. Similarly, CSPG4-selective binding activity of 
PD-L1xCSPG4 was confirmed by comparing binding to MDA-MB-231.CSPG4+++ cells 
versus parental CSPG4low MDA-MB-231 cells. In short, cancer cells were incubated with 
increasing concentrations of PD-L1xCSPG4 (0.001-10 µg/ml) at 4°C for 45 min, washed, 
incubated with anti-human-Ig-PE mAb and evaluated by flow cytometry. Additionally, 
binding selectivity of PD-L1xCSPG4 for endogenously expressed CSPG4 was assessed using 
CSPG4pos cancer cell lines A375m, G43, SK-MEL-28, A2058, HT1080, MDA-MB-435 
versus CSPG4neg cancer cell lines H292, FaDu, LNCaP, 22Rv1 by flow cytometry.  
 
Competitive binding assay  
The overall binding strength (avidity) of PD-L1xCSPG4, PD-L1xMock, and MockxCSPG4 
for PD-L1pos/CSPG4pos cancer cells was compared in a competitive binding assay. In short, 
















µg/ml) at 4°C for 45 min, after which PD-L1xCSPG4, PD-L1xMock or MockxCSPG4 was 
added in a concentration range from 0.01 to 50 µg/ml. After 1 h of incubation, an APC-
labeled PD-L1-blocking mAb was added (8 µg/ml) and allowed to compete with the 
respective test antibodies for PD-L1 or CSPG4 binding for 30 min, after which cell-bound 
APC levels were quantified by flow cytometry. 
 
CMV-specific T cell stimulation assay 
PBMCs derived from CMV-seronegative and CMV-seropositive healthy subjects were 
cultured in 96-well plates (1.5x105 cells/well) in the presence of recombinant CMV pp65 
protein according to manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, 
Germany). After 96 h, culture supernatants were harvested and stored at -20°C until analyzed 
for IFN-γ and Granzyme B secretion by ELISA. 
 
Mixed lymphocyte reaction 
The capacity of PD-L1xCSPG4 to promote activation and proliferation of T cells was 
assessed in a mixed lymphocyte reaction (MLR). In short, monocytes were isolated from 
PBMCs of health subjects by adherence to culture flasks and cultured with IL-4 (500 U/ml) 
and GM-CSF (800 U/ml). After 3 days, MoDCs were matured for an additional 24 h in the 
presence of IL-1β (5 µg/ml), IL-6 (15 µg/ml), TNF-α (20 µg/ml), and PGE2 (2.5 mg/ml), 
essentially as described before (Hobo et al, 2012). For the MLR, CFSE-labeled PBMCs were 
resuspended in RPMI/10% HS and stimulated with allogeneic MoDC at a cell ratio of 10 to 1. 
Subsequently, PD-L1xCSPG4 or appropriate control antibodies were added to the wells (5 
µg/ml). After 5 days of co-culturing, spent culture m dium was assayed for IFN-γ secretion. 


















Bioassay for CSPG4-directed PD-1/PD-L1 blockade by PD-L1xCSPG4 
Blockade of PD-1/PD-L1 interaction was assessed in a PD-1/PD-L1 Blockade Bioassay 
(Promega). This assay uses Jurkat-PD1-NFAT-luc T cells expressing PD-1 and NFAT-
inducible luciferase and CHO-PD-L1-CD3 cells expressing PD-L1 and a membrane-linked 
agonistic anti-CD3 antibody. When co-cultured, PD-1/PD-L1 interaction between both cell 
types inhibits TCR signaling and NFAT-mediated luciferase activity in Jurkat-PD1-NFAT-luc 
T cells. Addition of a PD-1/PD-L1 blocking agent results NFAT-mediated luciferase activity 
in Jurkat-PD1-NFAT-luc T cells. The capacity of PD-L1xCSPG4 for CSPG4-directed PD-
1/PD-L1 blockade was assessed by replacing CHO.PD-L1/CD3 cells by A375m.EpCAM 
cells (CSPG4pos/PD-L1pos) pretreated with BIS1; an EpCAM-directed CD3-agonistic bsAb. In 
short, Jurkat-PD1-NFAT-luc T cells were stimulated with BIS1 and mixed with 
A375m.EpCAM cells at a cell ratio of 5 to 1 and cultured for 18 h in the presence of PD-
L1xCSPG4 or appropriate control antibodies. Subsequently, Bio-Glo reagent was added after 
which bioluminescence was quantified using a Victor V3 multilabel plate reader (Perkin 
Elmer, Waltham, MA). 
 
IFN-γ ELISpot assay 
The enzyme-linked immunospot assay (ELISpot) (Thermo Fisher) was conducted according 
to the provided protocol. In brief, ELISpot plates (Merck Millipore, Darmstadt, Germany) 
were coated with anti-IFN-γ antibody and incubated overnight at 4°C. Plates were ashed and 
blocked with DMEM10% FCS for 1 h at RT. A375m, SK-MEL-28 or, FaDu cells were 
loaded with PD-L1xCSPG4 or control antibodies, after which unbound antibody was washed 
away. Cancer cells were plated (10.000 cells/well) and freshly isolated PBMCs, stimulated 
















incubated for 48 h at 37°C, washed and coated with de ection antibody for 2 h at RT. Next, 
plates were washed and coated with avidin-peroxidase for 45 min at RT. Plates were washed 
and developed by addition of aminoethylcarbazole (AEC) substrate. Developed plates were 
dried and read using an ImmunoSpot reader (AID, Autoimmun Diagnostika GmbH, 
Strassberg, Germany). 
 
Primary patient-derived melanoma cells and Tumor Infiltrating Lymphocytes  
Fresh melanoma tissue was collected during surgical resection after written informed consent 
(institutional approval by University Medical Center Groningen, nr. METc2012/330). Tissues 
were minced and short-term cultured in RPMI 1640/10% FCS. Adherent cell phenotype was 
analyzed by flow cytometry using fluorescently labeled CD14, PD-L1 and CSPG4 antibodies. 
Primary patient-derived melanoma cells used in this study were CD14neg and CSPG4pos and 
were used before passage 2. For generation of Tumor Infiltrating Lymphocytes (TILs), 
minced tissue fragments were cultured in RPMI 1640/10% FCS, supplemented with 50 IU/ml 
IL-2 (Proleukin, Novartis, Bazel, Swiss). TIL phenotype was confirmed by flow cytometry 
for CD3, CD4, CD8, PD-1 and PD-L1 expression (Suppl. Fig. 4a-c). 
 
Apoptosis assay 
Primary melanoma cells and autologous TILs were mixed in an E:T ratio of 2 to 1, in the 
presence or absence of PD-L1xCSPG4 or appropriate control antibodies (each 5 µg/ml). At 
day 3, apoptosis induction in cancer cells (Annexin-V) and CD25 expression on T cells were 



















Unless otherwise noted, values are mean ± SD. 
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Figure 1. PD-L1xCSPG4 binds to both PD-L1 and CSPG4 and retains capacity to 
activate T cells by blocking PD-1/PD-L1 interaction. (a) Dose-dependent binding of PD-
L1xCSPG4 to MDA-MB-231-CSPG4+++ cells (PD-L1pos/CSPG4pos) versus parental MDA-
MB-231 cells (PD-L1pos/CSPG4low). (b) Dose-dependent binding of PD-L1xCSPG4 to 
CHO.PD-L1 cells versus parental CHO cells. (c) Binding of PD-L1xCSPG4 (1 µg/ml) to 
A375m cells in the presence or absence of excess amounts of PD-L1-blocking antibody 
and/or CSPG4-competing mAb 9.2.27. (d) Binding of PD-L1xCSPG4 versus PD-L1xMock 
(5 µg/ml) to a series of PD-L1pos/CSPG4pos and PD-L1pos/CSPG4neg cancer cell lines. (e) 
Correlation between MFI of PD-L1xCSPG4 binding and MFI of CSPG4 expression of the 
same cell panel as in d. (f) Competitive binding assay in which anti-PD-L1-APC competes 
with increasing doses (0.01-50 µg/ml) of PD-L1xCSPG4 (black line) or PD-L1xMock (red 
line) for binding to A375m melanoma cells. Where indicated, A375m cells were pre-treated 
with excess amounts of mAb 9.2.27 (50 µg/ml) (blue line) or isotype control IgG2a (green 
line) for 15 min. Graphs a to c represent mean ± SD. R, correlation coefficient. 
 
Figure 2. PD-L1xCSPG4 blocks the PD-1/PD-L1 interaction in an CSPG4-directed 
manner. (a) CSPG4-independent blockade of the PD-1/PD-L1 interaction assessed by a 
commercially available PD-1/PD-L1 Blockade Bioassay (Promega). Mixed cultures of CHO-
K1.PD-L1 cells and Jurkat.PD-1-NFAT-luc cells were tr ated with increasing doses (0.01-50 
µg/ml) of PD-L1xCSPG4, PDL1xMock, MEDI4736 or isotype control. Luciferase activity in 
the Jurkat cells was quantified using a plate reader. (b) Capacity of the indicated test 
antibodies to dose-dependently (0.64-400 ng/ml) block PD-1/PD-L1 interaction in an CSPG4-
directed manner assessed in a modified version of the PD-1/PD-L1 bioassay in which 
















BIS-1; an EpCAM-directed CD3-agonistic bsAb (14). (c  Luciferase activity induced by PD-
L1xCSPG4 or PD-L1xMock in the presence or absence of xcess amounts of CSPG4-
competing mAb 9.2.27. 
 
Figure 3. PD-L1xCSPG4 enhances activation status of antigen-experienced T cells. (a) 
Representative histograms of fluorescence dilution of CFSE-labeled PBMCs mixed with 
allogeneic DCs in an MLR, co-treated with PD-L1xCSPG4 (5 µg/ml) or control antibodies for 
5 d. Representative of four independent experiments. (b) IFN-γ was measured in four 
different experiments, performed as in a. (c) PBMCs derived from CMV-seropositive or 
CMV-seronegative subjects were treated with PD-L1xCSPG4 (5 µg/ml) or control antibodies 
in the presence of CMV protein pp65 for 96 h. IFN-γ or (d) Granzyme B levels excreted in 
culture supernatant were determined by ELISA. Experim nts a to d were analyzed by flow 
cytometry. Graphs c and d represent mean ± SD. 
 
Figure 4. PD-L1xCSPG4 enhances anticancer activity of T cells towards CSPG4pos 
melanoma cells. (a) PBMCs (effector cells) were sub-optimally activated using an agonistic 
anti-CD3 antibody and then added to the A375m targe cells at an E:T cell ratio of 2:1. PD-
L1xCSPG4 (5 µg/ml) or control antibodies were added to the wells. IFN-γ ELISpots per 
20.000 PBMCs corrected for medium control. (b) Photos showing IFN-γ ELISpots produced 
during mixed culture of PBMC with A375m cells (CSPG4pos), as described in a. (c) Cancer 
cells were treated with PD-L1xCSPG4 (5 µg/ml) or contr l antibodies at 4°C for 1h, after 
which unbound antibody was removed. PBMCs were activ ted using an agonistic anti-CD3 
antibody and then added to the cancer cells in an E:T cell ratio of 2:1 or 5:1. A375m cells 
(CSPG4pos), SK-MEL-28 cells (CSPG4pos) or FaDu (CSPG4neg) cells treated with PD-

















Figure 5. PD-L1xCSPG4 enhances anticancer activity of TILs towards autologous 
patient-derived melanoma cells. Histograms showing cell surface expression of (a) CSPG4 
(red) and (b) PD-L1 (red) on primary melanoma cells derived from 5 individual melanoma 
patients. Binding of isotype control antibody is shown in black. TILs derived from 5 
melanoma patients were cocultured with corresponding autologous melanoma cells in an E:T 
ratio of 2:1 and treated with PD-L1xCSPG4, or contrl antibodies (5µg/ml). The percentage 
of apoptotic cancer cell death (c) and the percentage of CD25 expression (d) on TILs were 
determined by flow cytometry. (e) IFN-γ levels in culture supernatant of C as detected by 












































































Suppl. Fig 1. Construction and production of PD-L1xCSPG4. (a) A eukaryotic expression 
plasmid pEE14-bsAb, which contains 3 consecutive multiple cloning sites (MCS). MCS#1 
and MCS#2 are interspersed by a 22 amino acid flexibl  l nker derived from a CH1 IgG 
domain. MCS#1, MCS#2 and MCS#3 were used for directional and in-frame insertion of 
DNA fragments encoding scFvPD-L1, scFvCSPG4, and human IgG1 Fc domain, 
respectively, yielding plasmid pEE14-PD-L1xCSPG4. DNA fragments encoding scFvPD-L1 
and scFv9.2.27 were generated by commercial gene synthesis service (Genscript, Piscataway, 
NJ) based on published VH and VL sequence data of PD-L1-blocking antibody 3G10 and 
CSPG4-directed mAb 9.2.27 from patents US2011020923A1 and US20050244416A1, 
respectively. (b) Schematic representation of PD-L1xCSPG4. scFvPD-L1 (light blue); 
scFvCSPG4 (red); human Fc-IgG1 (dark blue). (c  SDS-PAGE analysis of PD-L1xCSPG4. 
Protein A-purified MEDI4736 (lane 1 and 2) or PD-L1xCSPG4 (lane 3 and 4) (2,5µg/ml 
each) were separated by an SDS-PAGE gel with or without reduction. Under non-reducing 
conditions PD-L1xCSPG4 has an apparent molecular weight of 175 kDa (lane 3), which 
dropped to 80 kDa under reducing conditions (lane 4). MEDI4736 showed the expected 
heterodimeric composition of heavy and light chain characteristic for conventional antibodies 
(lane 1 and 2). M, marker. NR, non-reduced. R, reduc . 
 
Suppl. Fig 2. Correlation PD-L1xCSPG4 and PD-L1xMock binding and CSPG4 and 
PD-L1 cell surface expression. (a) Correlation between the MFI of PD-L1xMock binding 
and the MFI of CSPG4 expression. (b) Correlation between the MFI of PD-L1xCSPG4 
binding and the MFI of PD-L1 expression. (c) Correlation between the MFI of PD-L1xMock 
binding and the MFI of PD-L1 expression. (a) to (c) were performed on the same cell panel as 














Suppl. Fig 3a. PD-L1xCSPG4 simultaneously binds to CSPG4 on one cell type and PD-
L1 on a nearby other cell type forming cell clusters. Representative flow cytometer dot-
plots demonstrating that bsAb PD-L1xCSPG4 can simultaneously bind and cellularly bridge 
(DiD-labeled) CSPGhigh A375m melanoma cells and (CSFE-labeled) PD-L1high CHO.PD-L1 
cells as is evident from a marked increase in DiD/CFSE double-positive events. This 
aggregation is fully abrogated in the presence of a CSPG4-blocking antibody. 
 
Suppl. Fig. 3b. Percentage DiD/CSFE double-positive events upon incubation with 
indicated antibodies.  Control bsAb PD-L1xMock antibody equipped with an irrelevant 
second binding specificity, as well as the clinically used monospecific PD-L1-blocking 
antibody MEDI4736 (durvalumab), failed to enhance clustering of both cell types (black 
bars). Additionally, when the experiment was performed using PD-L1-negative parental CHO 
cells instead of CHO.PD-L1 cells, no enhanced cluster formation was observed (gray bars).  
 
Suppl. Fig 4. Marker expression on tumor-infiltrating lymphocytes. (a) TIL’s were 
stained with anti-CD3 and anti-CD8 antibodies. Percentages of T cells are presented in the 
plot. Percentage (b) and MFI (c) of PD-1 and PD-L1 expression on gated CD3 T cells. Data 
are representatives of two donors. MFI, mean fluorescence intensity. 
 
Suppl. Fig 5. Assessment of CSPG4 cell surface expression using secondary signal 
amplification. (a) CSPG4 expression level on A2058 melanoma cells as detected by using a 
primary FITC-conjugated anti-CSPG4 mAb only (one-stp method) compared to (b) CSPG4 
expression level detected after subsequent signal amp ification using alexafluor647 labeled 













expression level on primary patient-derived melanoma cells (MEL6) as detected by using a 
primary FITC-conjugated anti-CSPG4 mAb only (one-stp method) compared to (d) CSPG4 
expression level detected after subsequent signal amp ification using alexafluor647-labeled 














Supplementary Table I 
Relative indexes of cell surface expression of CSPG4 and PD-L1 by a series of cancer cell 
lines by flow cytometry using anti-CSPG4-FITC and anti-PD-L1-APC antibodies, 
respectively.  
 
Cell lines CSPG4 PD-L1 
A375m ++++ + 
G43 +++ + 
HT1080 +++ ++ 
SK-MEL-28 +++ +++ 
A2058 ++ + 
MDA-MB-231 + ++++ 
MDA-MB-231.CSPG4+++ ++++ ++++ 
MDA-MB-435 + + 
H292 - +++ 
LNCaP - ++ 
22RV1 - + 
FADU - ++++ 
  
relative expression index of CSPG4:  
 +  = MFI <10 
 ++  = MFI 10-30  
 +++  = MFI 30-50 
 ++++  = MFI >50 
 
relative expression index of PD-L1:  
 +  = MFI <40 
 ++  = MFI 40-60  
 +++  = MFI 60-80 
 ++++  = MFI >80 
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